Muslih Ürün

Dr. Muslih Ürün


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2024 in Medical Science Monitor
Verified
Journal Article
Open access
MÜMuslih Ürün
Muslih Ürün
GGGürkan Güner
Gürkan Güner
YSYasin Sezgin
Yasin Sezgin
EUEmre Uysal
Emre Uysal
ASAbdullah Sakin
Abdullah Sakin
SKSaadettin Kilickap
Saadettin Kilickap
BACKGROUND The advanced lung cancer inflammation index (ALI) is regarded as a potential indicator of systemic inflammation. This retrospective study aimed to evaluate the prognostic role of the ALI in 96 patients with advanced small cell lung cancer (SCLC). MATERIAL AND METHODS This retrospective study included 96 patients who were diagnosed with extensive stage SCLC in a single institution between 2016 and 2022. The formula for ALI is body mass index (kg/m²)×serum albumin (g/dL)/neutrophil to lymphocyte ratio. Patients were divided into low inflammation (ALI ≥32.5) and high inflammation (ALI <32.5) groups. Kaplan-Meier analysis and Cox proportional analysis were conducted to assess the association between the ALI and patient prognosis. RESULTS Median age was 61 (range: 41-82) years. Median follow-up was 9 months, and median overall survival (OS) was 10 months (95% CI: 7.75-12.45). A lower ALI score (ALI <32.5) was correlated with a poorer OS than was a higher ALI score (median OS 7 months for ALI <32.5 95% CI: 4.6-9.3 vs 15 months for ALI ≥32.5, 95% CI: 10.6-19.3, P<0.001). In the multivariate analysis, ALI score, Eastern Cooperative Oncology Group performance status, brain metastasis, and bone metastasis were identified as independent prognostic factors. CONCLUSIONS ALI score is a substantial predictor of survival in SCLC as in other types of cancer types. Patients with a low ALI score have poorer survival. Assessment of ALI can identify lung cancer patients at high risk of poor prognosis and can be a useful prognostic marker in clinical practice.

2 October 2024 in Heliyon
Verified
Journal Article
Open access
OAOmer Acar
Omer Acar
OBOnur Yazdan Balcik
Onur Yazdan Balcik
MÜMuslih Ürün
Muslih Ürün
TATUGAY AVCI
TUGAY AVCI
MSMustafa Sahbazlar
Mustafa Sahbazlar
AEAtike Pinar Erdogan
Atike Pinar Erdogan
The pivotal prognostic determinant for recurrence and survival in surgically treated gastric cancer (GC) patients remains the lymph node status. Despite the adoption of D2 lymph node dissection as the standard approach in recent years, its association with increased morbidity in elderly patients raises concerns. This study aims to explore the prognostic significance of the Positive Lymph Node Ratio (PLNR) score in the context of recurrence and survival among elderly patients with surgically treated GC. A retrospective review of files about surgically treated patients with GC was conducted. The prognostic impact of the PLNR score on overall survival (OS) was assessed through Receiver Operating Characteristic (ROC) analysis. The cut-off value for the PLNR, determined through ROC analysis, was identified as 0.138. This value serves as a crucial threshold, as it distinguishes patients with a higher risk of poor outcomes. Patients with a PLNR score of 0.138 or below exhibited a median OS of 111 months, whereas those with a PLNR score above 0.138 had a significantly lower median OS of 22 months (p = 0.004). Our findings revealed that the PLNR emerged as an independent predictor of survival and recurrence in patients undergoing GC resection.However, it's important to note that while valuable, the PLNR system has limitations. It does not encompass the T stage, a key factor in cancer staging. Therefore, it cannot be a direct substitute for the comprehensive information TNM staging provides. It should be used as a supplementary tool in predicting prognosis, particularly in elderly patients unsuitable for standard lymph node dissection.

13 February 2026 in Biomarkers
Verified
Journal Article
Closed access
IBIsmail Beypinar
Ismail Beypinar
OBOnur Yazdan Balçık
Onur Yazdan Balçık
SUSemiha Urvay
Semiha Urvay
MÜMuslih Ürün
Muslih Ürün
BEBerrak Mermit Ercek
Berrak Mermit Ercek
AKAziz Kurtulus
Aziz Kurtulus
AimInflammation and immune dysfunction significantly impact cancer progression and treatment responses. This retrospective study investigated inflammatory parameters and ferritin in predicting immunotherapy response in non-small cell lung cancer (NSCLC) patients.MethodsThe study included 199 patients with NSCLC who received nivolumab between 2018 and 2024 at five medical centers. Various inflammatory markers were also evaluated. Ferritin levels at diagnosis and pretreatment were also evaluated.ResultsROC curve analyses showed ferritin delta had high prognostic performance for PFS and OS, with AUC values of 0.70 and 0.73. PIV and PNI were significantly associated with PFS and OS. In Kaplan-Meier analyses, PNI was the most consistent prognostic factor. Low PNI (≤43.5) significantly associated with shorter OS (5.0 vs. 15.0 months, p = 0.001) and shorter PFS (4.0 vs. 8.0 months, p = 0.002). High mGPS (score 2) and elevated PIV showed significant prognostic value. In multivariate Cox regression, PNI demonstrated independent prognostic significance. Objective response rate was the strongest prognostic factor for PFS (HR = 0.188, 95%CI: 0.114-0.309, p < 0.001).ConclusionThese findings highlight the prognostic value of inflammatory and nutritional markers in patients with NSCLC receiving immunotherapy. PNI demonstrated the most consistent prognostic value across multiple analytical approaches and maintained significance in the multivariate analysis.

14 April 2026 in Scientific Reports
Verified
Journal Article
Open access
GAGözde Ağdaş
Gözde Ağdaş
DGduygu bayır garbioglu
duygu bayır garbioglu
ESElif Sahin
Elif Sahin
MCMuhammet Cengi̇z
Muhammet Cengi̇z
DGDeniz Can Guven
Deniz Can Guven
IKibrahim karadağ
ibrahim karadağ
Immune checkpoint inhibitors such as nivolumab have brought meaningful benefits to patients with advanced non-small cell lung cancer (NSCLC), yet many patients still experience limited responses. Vitamin D is a key modulator of immune function, and deficiency is common in individuals with cancer. Given its potential role in shaping immunotherapy response, we retrospectively assessed whether baseline vitamin D levels were associated with clinical outcomes in advanced NSCLC patients treated with nivolumab. We retrospectively analyzed patients with stage IV NSCLC treated with nivolumab across multiple centers, predominantly as second-line therapy. Prior to nivolumab initiation, all patients were confirmed to be negative for common driver mutations, including EGFR, ALK, ROS1, and other actionable genomic alterations. Baseline serum 25-hydroxyvitamin D levels were measured prior to nivolumab initiation, and patients were categorized as having severe deficiency (< 10 ng/mL), deficiency (10–20 ng/mL), or sufficient levels (≥ 20 ng/mL). The presence of liver metastases was recorded at baseline. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared with log-rank tests. Multivariable Cox proportional hazards models adjusted for age, sex, ECOG performance status, liver metastasis, and other metastatic sites were used to evaluate the independent prognostic value of vitamin D status. Objective response rates (ORR) were assessed in patients with available radiologic data. A total of 890 patients were screened, and after excluding those with missing baseline vitamin D data, 305 patients were included in the analysis. The median age was 64 years (range 34–85), and 68% of patients were male. Vitamin D levels were < 10 ng/mL in 30%, 10–20 ng/mL in 44%, and ≥ 20 ng/mL in 26% of patients. Patients with severe vitamin D deficiency were numerically older (median age 65 vs. 63 years) and had higher rates of ECOG PS ≥ 2 (15.1% vs. 7.5%) and squamous histology (37.6% vs. 27.5%), though these differences were not statistically significant (p > 0.05 for all). Liver metastases were present in 54 patients (17.7%), and the distribution was similar across vitamin D groups (p = 0.92). Median PFS was shortest in patients with severe vitamin D deficiency (3.4 months), intermediate in the 10–20 ng/mL group (5.2 months), and longest in patients with sufficient levels (8.1 months). Median OS ranged from 8.6 months in the < 10 ng/mL group to 15.8 months in the ≥ 20 ng/mL group. Patients with liver metastases had significantly shorter OS compared to those without (median OS 9.8 vs. 13.6 months, HR 1.48, p = 0.006). Vitamin D deficiency was associated with significantly worse PFS and OS on univariate analysis. In multivariable analysis, vitamin D levels < 20 ng/mL remained independently associated with poorer OS. ORR was numerically higher in patients with sufficient vitamin D levels (30% vs. 14%). Lower baseline vitamin D levels were associated with inferior clinical outcomes in advanced NSCLC patients treated with nivolumab. Patients with vitamin D levels ≥ 20 ng/mL demonstrated longer PFS and OS and a trend toward higher response rates. These findings support a prognostic role for vitamin D status in immunotherapy-treated NSCLC; however, prospective studies are required to determine whether vitamin D optimization can causally enhance immunotherapy efficacy.

4 November 2024 in Medical Science Monitor
Verified
Journal Article
Open access
MÜMuslih Ürün
Muslih Ürün
GGGürkan Güner
Gürkan Güner
YSYasin Sezgin
Yasin Sezgin
ASAbdullah Sakin
Abdullah Sakin
SKSaadettin Kılıçkap
Saadettin Kılıçkap
Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer - Article abstract #946751

19 February 2025 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
IBIsmail Beypinar
Ismail Beypinar
SUSemiha Urvay
Semiha Urvay
MÜMuslih Ürün
Muslih Ürün
BEBerrak Mermit Ercek
Berrak Mermit Ercek
HDHACER DEMİR
HACER DEMİR
OBOnur Yazdan Balçık
Onur Yazdan Balçık